Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
Healthcare | Drug Manufacturers - Major | USA
financial highlights | statements
IndexDJIA S&P500 P/E20.04 EPS (ttm)2.18 Insider Own0.04% Shs Outstand5.87B Perf Week2.10%
Market Cap256.64B Forward P/E14.14 EPS next Y3.09 Insider Trans-28.54% Shs Float5.86B Perf Month3.77%
Income13.15B PEG2.67 EPS next Q0.74 Inst Own72.80% Short Float0.83% Perf Quarter20.52%
Sales53.24B P/S4.82 EPS this Y68.20% Inst Trans0.04% Short Ratio2.46 Perf Half Y22.89%
Book/sh11.89 P/B3.68 EPS next Y3.48% ROA13.40% Target Price41.80 Perf Year21.56%
Cash/sh2.29 P/C19.11 EPS next 5Y7.52% ROE33.20% 52W Range33.20 - 43.68 Perf YTD20.79%
Dividend1.36 P/FCF31.03 EPS past 5Y10.40% ROI11.00% 52W High0.16% Beta0.95
Dividend %3.11% Quick Ratio0.90 Sales past 5Y-0.80% Gross Margin78.90% 52W Low31.78% ATR0.59
Employees90200 Current Ratio1.20 Sales Q/Q4.40% Oper. Margin25.40% RSI (14)76.30 Volatility1.40% 1.39%
OptionableYes Debt/Eq0.58 EPS Q/Q27.90% Profit Margin42.30% Rel Volume0.88 Prev Close43.26
ShortableYes LT Debt/Eq0.41 EarningsJul 31 BMO Payout34.80% Avg Volume19.74M Price43.75
Recom2.80 SMA203.69% SMA507.87% SMA20017.38% Volume17,476,184 Change1.13%
Jun-08-18Initiated Cantor Fitzgerald Overweight $45
Apr-05-18Downgrade Barclays Overweight → Equal Weight $41 → $38
Jan-29-18Reiterated SunTrust Hold $33 → $40
Sep-20-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-20-17Downgrade Credit Suisse Outperform → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Sep-20-18 07:48PM  [$$] Companies Stockpile Drugs, Chocolate as They Brace for Hard Brexit The Wall Street Journal
11:00AM  Eli Lilly Prices Animal Health Unit IPO at $24 Per Share Zacks
10:54AM  Merck or Pfizer: Which is the Better Large-Cap Pharma Stock? Zacks
08:00AM  Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older Business Wire
06:07AM  [$$] Companies' Brexit Challenge: Preparing for the Unknown The Wall Street Journal
Sep-19-18 08:00AM  Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Pfizer ACCESSWIRE
Sep-18-18 02:57PM  Health care ETF surges toward record in a broad sector rally MarketWatch
02:45PM  New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting Business Wire
10:00AM  Pfizer Invites Public to View and Listen to Webcast of October 30 Conference Call with Analysts Business Wire
08:33AM  Is the Options Market Predicting a Spike in Pfizer (PFE) Stock? Zacks
08:13AM  Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth? Zacks
02:09AM  Cronos Gets Bigger As It Partners With Ginkgo Bioworks InvestorPlace
Sep-17-18 06:27PM  Pfizer's Skin Disease Candidates Positive in Mid-Stage Study Zacks
10:03AM  This cancer-fighting biotech sped from startup to IPO filing in 10 months American City Business Journals
Sep-15-18 02:00AM  Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress Business Wire
Sep-14-18 05:45PM  Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know Zacks
10:02AM  Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus Zacks
09:43AM  Pharma/Biotech Stocks to Watch This Prostate Cancer Month Zacks
07:21AM  Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal Zacks
06:15AM  A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis Motley Fool
Sep-12-18 03:09PM  How Companies Are Getting Ready for Hurricane Florence Bloomberg
11:25AM  The Outlook for AstraZeneca Is Positive, But Its Too Early to Pull the Trigger InvestorPlace
09:43AM  Pfizer's Drug Combo Betters Survival in Kidney Cancer Study Zacks
Sep-11-18 01:07PM  Pfizer to Idle Plants in North Carolina With Hurricane Florence Approaching Bloomberg
09:13AM  Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer Reuters
Sep-10-18 04:45PM  Apple, Snap Weak Again; Will This Sector Help Dow Beat Nasdaq In Q3? Investor's Business Daily
08:04AM  The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson Zacks
Sep-09-18 06:31AM  Is Bristol-Myers Squibb Company a Buy? Motley Fool
Sep-08-18 05:52PM  Two more Peninsula IPOs tell the story of biotech's investment boom American City Business Journals
Sep-07-18 10:41AM  Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus Zacks
10:21AM  AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status Zacks
09:30AM  Your first trade for Friday, Sept 7 CNBC
08:58AM  Lilly, Teva, Pfizer & Others Await FDA Decisions in September Zacks
08:35AM  Dow 30 Stock Roundup: Coca-Cola Buys Costa, DowDuPont Earnings Impress Zacks
06:00AM  Why Exact Sciences Corporation Stock Rocketed Higher in August Motley Fool
Sep-06-18 06:56PM  [$$] SpringWorks Joins BeiGene in Cancer Drug Collaboration The Wall Street Journal
02:12PM  These Hospital Systems Are Aiming To Undercut Biotechs, Drugmakers Investor's Business Daily
11:30AM  Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire
10:57AM  Pfizer's Skin Disease Drug Gets Breakthrough Therapy Status Zacks
09:57AM  Large Cap Pharma Stocks Staging a Comeback in Second Half Zacks
09:01AM  The Zacks Analyst Blog Highlights: Pfizer, Salesforce, ADP, General Motors and Southwest Airlines Zacks
08:48AM  Sangamo's Zinc Fingers Fail Again. Time to Walk Away? Motley Fool
08:00AM  Walgreens to offer Auvi-Q as EpiPen shortage challenges parents CNBC
07:02AM  Lilly's Elanco unit expects IPO to raise up to $1.45 bln Reuters
06:30AM  3 Top Big Pharma Stocks to Buy Now Motley Fool
06:00AM  Date rape drug test allows women to discreetly check for spiked drinks with a few drops CNBC
Sep-05-18 08:05PM  [$$] Big Pharma Catches Up With Biotech The Wall Street Journal
07:10PM  [$$] SpringWorks Therapeutics Names Saqib Islam as CEO The Wall Street Journal
04:14PM  Top Analyst Reports for Pfizer, Salesforce & ADP Zacks
08:50AM  Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata Business Wire
08:30AM  3 Biotech Stocks Ready to Burn Up TheStreet.com
07:26AM  [$$] Big Pharma Catches Up With Biotech The Wall Street Journal
Sep-04-18 08:38PM  Pfizer Prices $5,000,000,000 Debt Offering Business Wire
10:00AM  TREASURIES-Yields rise as investors prepare for corporate debt supply Reuters
09:31AM  Better Buy: Pfizer Inc. vs. Eli Lilly and Company Motley Fool
09:11AM  Mylan Suffers Several Setbacks: What's in Store in 2H18? Zacks
06:12AM  Pfizer says getting ready for Brexit will cost $100m Evening Standard
12:00AM  Pfizer Estimates Brexit Costs at $100 Million as Talks Drag Bloomberg
Aug-31-18 05:35PM  Biotech Fund Flows, Including ETF Activity, Remain a Driver to Watch ETF Trends
01:28PM  One sector is beating tech this quarter, but one technician sees a ceiling CNBC
10:42AM  Pfizer Discontinues Studies on DMD Candidate Domagrozumab Zacks
10:19AM  Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus Zacks
08:39AM  4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline Zacks
Aug-30-18 12:47PM  Scholar Rock stock tumbles 11% as Pfizer discontinues similar medication MarketWatch
12:27PM  Pfizer (PFE) Up 3.1% Since Last Earnings Report: Can It Continue? Zacks
09:24AM  Amgen's Leukemia Drug Blincyto Gets EU Nod for Pediatric Use Zacks
09:16AM  Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar? Zacks
08:28AM  Pfizer stops developing therapy for the rare disease Duchenne muscular dystrophy MarketWatch
08:00AM  Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy Business Wire
Aug-29-18 05:45PM  Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know Zacks
09:30AM  Pfizer Stock Up This Year So Far: What's Going in its Favor? Zacks
Aug-28-18 06:40PM  3 ETFs for Johnson & Johnson's Healthy Breakout Investopedia
10:36AM  Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study Zacks
09:31AM  6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug Motley Fool
08:23AM  Pfizer stock drops 2% as positive rare-disease drug results wont stop competitors MarketWatch
08:00AM  Todays Research Reports on Stocks to Watch: Pfizer and Alnylam Pharmaceuticals ACCESSWIRE
Aug-27-18 06:19PM  All-Time highs: 6 stocks to buy CNBC Videos
05:42PM  Why Pfizer (PFE) Stock Turned South Today InvestorPlace
05:01PM  What Happened in the Stock Market Today Motley Fool
04:38PM  General Motors and Caterpillar jump; Tesla and Pfizer skid Associated Press
02:59PM  Pfizer Slips Despite Mostly Positive Tafamidis Data; 4 Pharma Stocks Make Sympathy Moves Benzinga
01:07PM  Here's Why Alnylam Pharmaceuticals and Ionis Pharmaceuticals Jumped Today Motley Fool
08:38AM  Pfizer rare-disease drug results lift its shares and those of rival MarketWatch
07:41AM  US STOCKS-Futures rise as trade tensions ease Reuters
05:21AM  Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented as Late-Breaking Data at the ESC Congress 2018 Business Wire
05:01AM  Pfizer's Potential Blockbuster Heart Drug Boosted by Study Bloomberg
05:00AM  Pfizer rare heart disease drug reduces risk of death by 30 pct in study Reuters
Aug-26-18 09:22PM  EpiPen Shortage Hits Back-to-School Season The Wall Street Journal
05:33PM  Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside TheStreet.com
03:40PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results Benzinga
Aug-25-18 09:49AM  What is Behind Pfizer Incs (NYSE:PFE) Superior ROE? Simply Wall St.
09:00AM  EpiPen Shortage Hits Back-to-School Season The Wall Street Journal
Aug-24-18 11:41AM  Merck, Pfizer to Benefit From Pharma Surge: MS Investopedia
08:54AM  Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs Zacks
Aug-23-18 03:12PM  Big Pharma's Big Run Isn't Done Barrons.com
12:57PM  Why Exact Sciences Corporation Stock Is Jumping Again Today Motley Fool
11:00AM  Pfizer Amends Xtandi Study Protocols to Speed Up Completion Zacks
10:54AM  Exact Sciences Inks Cologuard Co-Promotion Deal With Pfizer Zacks
08:54AM  Is the Options Market Predicting a Spike in Pfizer (PFE) Stock? Zacks
07:00AM  Pfizer's Next Blockbuster Drug Has Big Promise. We'll Find Out Monday How Much. Bloomberg
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brands. This segment also engages in the research and development, as well as contract manufacturing activities. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company for the development of Eliquis; Astellas Pharma US, Inc. for developing Xtandi; Merck KGaA for the development of Bavencio; BioNTech AG for the research and development of mRNA-based vaccines for the prevention of influenza; and Neofluidics, LLC to develop a microfluidics-based platform, as well as development agreement with Antares Pharma, Inc. to develop a combination drug device rescue pen. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dolsten MikaelPresident R&DSep 13Option Exercise24.56181,7124,462,167234,299Sep 17 04:08 PM
OLSON LAURIE JExecutive Vice PresidentAug 13Sale41.0010,214418,77472,672Aug 14 05:04 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentAug 03Sale39.5125,6421,013,171102,412Aug 06 03:19 PM
GOETTLER MICHAELGroup PresidentAug 01Sale39.7019,198762,11611,924Aug 03 03:38 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerAug 01Sale40.1626,8141,076,93383,846Aug 03 03:36 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentAug 01Sale40.0420,942838,5724,643Aug 03 03:35 PM
DAMELIO FRANK AExecutive Vice PresidentAug 01Sale40.00150,4846,019,360337,391Aug 03 03:33 PM
SUSMAN SALLYExecutive Vice PresidentJul 20Sale37.2240,3811,502,925115,096Jul 24 01:09 PM
READ IAN CChairman & CEOJul 16Sale37.36486,75318,186,315659,440Jul 17 04:59 PM
OLSON LAURIE JExecutive Vice PresidentJun 06Sale36.4519,000692,58282,886Jun 08 01:11 PM
CORNWELL W DONDirectorJun 04Sale36.405,223190,1170Jun 05 04:44 PM
READ IAN CChairman & CEOMay 01Sale36.01132,3124,764,0811,144,703May 03 04:19 PM
JOHNSON RADY AExecutive Vice PresidentMar 13Sale36.5527,323998,66643,178Mar 14 05:19 PM
LANKLER DOUGLAS MExecutive Vice PresidentMar 13Sale36.8950,0001,844,39883,857Mar 14 05:13 PM
Dolsten MikaelPresident R&DMar 09Sale36.5969,6992,550,39451,185Mar 12 05:01 PM
HILL CHARLES HExecutive Vice PresidentMar 06Sale35.7642,3931,515,98557,328Mar 07 04:09 PM
Dolsten MikaelPresident R&DMar 02Sale35.8513,986501,398120,884Mar 05 09:23 AM
HILL CHARLES HExecutive Vice PresidentFeb 28Option Exercise27.37101,8722,788,237207,942Mar 02 03:24 PM
YOUNG JOHN DGroup PresidentFeb 28Option Exercise27.37121,1453,315,739362,707Mar 02 04:10 PM
OLSON LAURIE JExecutive Vice PresidentFeb 28Option Exercise27.3738,5461,055,004132,702Mar 02 04:02 PM
READ IAN CChairman & CEOFeb 28Option Exercise27.37649,78017,784,4791,774,184Mar 02 04:03 PM
SUSMAN SALLYExecutive Vice PresidentFeb 28Option Exercise27.37110,1323,014,313245,362Mar 02 04:03 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 28Option Exercise27.3719,273527,50239,801Mar 02 03:44 PM
JOHNSON RADY AExecutive Vice PresidentFeb 28Option Exercise27.3719,273527,50285,910Mar 02 03:44 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 28Option Exercise27.3746,8061,281,080171,276Mar 02 03:44 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 28Option Exercise27.37104,6262,863,614384,219Mar 02 03:44 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 28Option Exercise27.37209,2515,727,200655,161Mar 02 03:24 PM
BOURLA ALBERTChief Operating OfficerFeb 28Option Exercise27.3739,9231,092,693184,120Mar 02 03:24 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 28Option Exercise27.3733,040904,305136,847Mar 02 03:24 PM
Dolsten MikaelPresident R&DFeb 28Option Exercise27.37198,2385,425,774293,352Mar 02 03:24 PM
HILL CHARLES HExecutive Vice PresidentFeb 28Sale36.8326,779986,292181,163Mar 02 03:24 PM
SUSMAN SALLYExecutive Vice PresidentFeb 27Sale37.0333,3681,235,591135,230Feb 28 06:14 PM
Dolsten MikaelPresident R&DFeb 27Sale37.0464,5872,392,31395,114Feb 28 06:04 PM
CORNWELL W DONDirectorFeb 27Sale37.0530011,1150Feb 28 01:29 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 26Sale37.199,510353,67717,770Feb 27 07:38 PM
CORNWELL W DONDirectorFeb 26Sale36.741,45853,5640Feb 28 01:29 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9043,520822,528223,733Feb 27 08:59 PM
READ IAN CChairman & CEOFeb 24Option Exercise19.83903,55917,917,2651,560,007Feb 27 08:58 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9015,716297,03290,222Feb 27 07:53 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.9091,8761,736,456206,972Feb 27 07:51 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9015,885300,22762,848Feb 27 07:43 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9028,288534,643112,081Feb 27 07:43 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.9091,8761,736,456313,499Feb 27 07:43 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 24Option Exercise18.9015,957301,58736,959Feb 27 07:38 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentFeb 24Option Exercise18.9039,555747,590143,152Feb 27 07:38 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9065,2801,233,792122,609Feb 27 07:38 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90174,0813,290,131225,265Feb 27 07:32 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9028,288534,643116,769Feb 27 07:30 PM
BOURLA ALBERTChief Operating OfficerFeb 24Option Exercise18.9025,387479,814158,170Feb 27 07:30 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90174,0813,290,131511,470Feb 27 07:30 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentDec 15Sale37.006,750249,750103,458Dec 18 06:17 PM
JOHNSON RADY AExecutive Vice PresidentDec 15Sale37.078,000296,56046,963Dec 18 06:17 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentNov 01Sale34.947,350256,809110,082Nov 02 07:03 PM
PFIZER INC10% OwnerOct 10Buy17.0040,000680,0001,427,639Oct 10 04:22 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentOct 02Sale35.657,350262,028117,432Nov 02 07:03 PM
open in yahoo | open in reuters | open in google